DOCSLIB.ORG

JANUARY 2014 S. No Principal Investigator Department Title Fund

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
JANUARY 2014 S. No Principal Investigator Department Title Fund LIST OF STUDIES WITH RESPECTIVE FUNDING AGENCY JANUARY 2006 – JANUARY 2014 Principal S. No Department Title Funding Agency Investigator A randomized, double-blind, placebo-controlled, parallel group study to determine whether, in patients with type 2 diabetes at AACT – Academic 1 Dr. Nihal Thomas Endocrinology high risk for cardiovascular and renal events, aliskiren, on top of Alliance for Clinical conventional treatment, reduces cardiovascular and renal Trials morbidity and mortality. This prospective, open label, multi –center, observational, single- 2 Dr. Sunil Chandy Cardiology arm registry is designed to XIENCE VEECSS continued safety and Abbott Vascular effectiveness during commercial use in real world settings. Prospective, randomized, placebo-controlled, double-blind, Dr. Debashish Clinical Immunology multicenter, parallel group study to assess the efficacy, safety and 3 Actelion Danda & Rheumatology tolerability of macitentan in patients with ischemic digital ulcers associated with systemic sclerosis. Targeted Second- Generation Resequencing for the Molecular 4 Dr. Nihal Thomas Endocrinology Genetic Diagnosis of Maturity Onset Diabetes of the Young Actelion (MODY). A randomized, active therapy controlled phase 2 study to assess Advaxis Inc, North 5 Dr. Subhashini John Radiation Therapy the safety and efficacy of ADXS11-001 with or without Cisplatin Brunswick as 2nd line therapy for the treatment of recurrent cervix cancer. A multicentre, open label, parallel group, randomized, phase IIB Adventrux Dr. Raju Titus clinical trial to evaluate the safety and efficacy of CofactorTM and 6 Medical Oncology Pharmaceuticals, Chacko 5-FU versus Leucovorin and 5-FU in subjects with Metastatic USA colorectal carcinoma. FORTIS-M: A phase 3, randomized, double-blind, placebo- controlled study of oral talactoferrin in addition to best 7 Dr. Subhashini John Radiotherapy Agennix Inc. supportive care in patients with non-small cell lung cancer who have failed two or more prior treatment regimens. AIDS International The BV study: Relationship of Lactobacillus and its phages in training and 8 Dr. Shalini Anandan Clinical Microbiology bacterial vaginosis among women in India. research programme An evaluation of the safety and efficacy of Moxifloxacin AF Dr. Andrew 9 Ophthalmology Opthalmic solution 0.5% for the treatment of Bacterial Alcon Research Ltd. Braganza conjunctivitis in India. A 6 day, Phase 3, Multicenter, Randomized, Double-Masked, Parallel Study to compare the safety and efficacy of Gatifloxacin 10 Dr. Sanita Korah Ophthalmology Allergan 0.5% ophthalmic solution BID with that of vehicle in the treatment of acute bacterial conjunctivitis. Allergan. A Multicentric, double blind, randomized, placebo controlled, paralled group, study to explore the dose dependent response to 11 Dr. Ninan K Chacko Urology three dose levels of Botox (Botulinum Toxin Type A) purified Allergan neurotoxin complex followed by an open label extension phase in patients with urinary incontinence due to neurogenic detrusor overactivity. A multicentric, double blind, randomized, placebo controlled, paralled group, study to explore the dose dependent response to 12 Dr. Ninan K Chacko Urology three dose levels of Botox purified neurotoxin complex followed Allergan by an open label extension phase in patients with urinary incontinence due to neurogenic detrusor overactivity. A randomized, double blind, multicenter, study of Denosumab compared with Zolerdronic Acid (Zometa) in the treatment of 13 Dr. Subhashini John Radiotherapy II Amgen Inc bone metastases in men with hormone refractory prostate cancer. A randomized, double blind, multicenter, study of Denosumab 14 Dr. Subhashini John Radiotherapy II compared with Zolerdronic Acid (Zometa) in the treatment of Amgen Inc bone metastases in subjects with advanced breast cancer. A randomized, double-blind, multicenter study of Denosumab Dr. Raju Titus compared with zoledronic acid (Zometa) in the treatment of bone 15 Medical Oncology Amgen Inc, USA Chacko metastases in subjects with Advanced Cancer (excluding breast and prostate cancer) or multiple myeloma. A phase 2, multicenter, open label, randomized trial of AMG 706 Dr. Raju Titus or Bevacizumab in combination with Paclitaxel and Carboplatin 16 Medical Oncology Amgen Inc. Chacko for advanced non-squamous non-small cell lung cancer. Protocol No. 20060136. 17 Dr. Thomas V Paul Endocrinology A Multicenter, International, randomized, Double-blind, Placebo- Amgen, Inc controlled, Parallel-group study to Assess the Efficacy and Safety of AMG 785 Treatment in Postmenopausal Women with Osteoporosis. Aquaya Institute, Qualitative investigation of community & professional groups in CA, USA and 18 Dr. Vinohar Balraj Community Health India and their interest in water testing. University of Bristol Assessment of an anti-TFPI aptamer: ARC19499 in correcting the Archemix Corp, 19 Dr. Alok Srivastava Haematology abnormal hemostasis of blood from patients with hemophilia and Cambridge, MA, evaluation of its concentration-effect relationship. USA An open-label study investigating long-term safety and tolerability of Nasalfent (Fentanyl Citrate Nasal Spray) in the Archimedes 20 Dr. Reena George Palliative Care Unit treatment of Breakthrough Cancer Pain (BTCP) in patients taking Development Ltd. regular opioid therapy. Improving health worker and Emergency medical technician and 21 Dr. Anand Zachariah Medicine Emergency response centre physician knowledge, skills and Asia Pacific practice in first aid and transport in acute poisoning Asian Network for A multicenter, multinational serosurvey study for Pertussis 22 Dr. V. Balaji Clinical Microbiology Study of Resistant among children 10-18 years old in Asia Pathogens 23 Dr. Debashish Clinical Immunology ACR/EULAR diagnostic and classification criteria for vasculitis Association of Danda & Rheumatology Medical Toxicology An open label, multi-centre, prospective study to demonstrate Astellas Pharma 24 Dr. V. Tamilarasi Nephrology safety and efficacy of once daily Advagraf in patients undergoing India Pvt. Ltd kidney or liver transplantation in India. A double blind, placebo controlled, parallel group, multicentre, randomized, Get Ethics phase 11 survival study comparing ZD AstraZeneca Dr. Raju Titus 1839 (IRESSATM ) (250 mg tablet) plus Committee best 25 Medical Oncology Pharma Private Chacko supportive care in patients with advanced NSCLC who have Limited, Bangalore received one or two prior chemotherapy regimens and who are refractory or intolerant to their most recent regimen. A Multicentre, Randomised, Double-blind, placebo-controlled, AstraZeneca 26 Dr. Dilip Mathai Medicine Unit I study on the use of Prophylactic Meropenem in patients with Pharma Private Severe Acute Necrotizing Pancreatitis. Limited, Bangalore A phase II randomized, double blind, placebo controlled, multicentre comparative study of ZD1839 250 mg or 500 mg AstraZeneca (IressaTM) given either continuously or concomitantly with 27 Dr. Subhashini John Radiotherapy - II Pharma Private Cisplatin plus Radiotherapy for the treatment of patients with Limited, Bangalore previously untreated unresected late stage III/IV non-metastatic Head and Neck squamous cell carcinoma. A Phase II, Randomised, Double-blind, Placebo-controlled, Multi- centre Study to Assess the Efficacy and Safety of AZD8931 In AstraZeneca 28 Dr. Subhashini John Radiotherapy Combination with Anastrozole, Compared to Anastrozole alone, Pharma Private in Post-menopausal Women With Hormone Receptor-positive, Limited, Bangalore Endocrine Therapy-naive, Locally-advanced or Metastatic Breast Cancer (MINT) A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous AstraZeneca 29 Dr. DJ Christopher Pulmonary Medicine Ceftaroline Fosamil Versus Intravenous Ceftriaxone in the Pharma Private Treatment of Adult Hospitalised Patients With Community- Limited, Bangalore Acquired Bacterial Pneumonia in Asia. A phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 10 mg ZD4054 in combination AstraZeneca Dr. Raju Titus 30 Medical Oncology with docetaxel in comparison with doccetaxel in comparison Pharma Private Chacko with docetaxel in patients with metastatic hormone-resistant Limited, Bangalore prostate cancer. A phase III, randomized, double-blinded, multi-center study to assess the efficacy of Docetaxel (TAXOTERETM) in combination AstraZeneca Dr. Raju Titus with ZD6474 (ZACTIMATM) versus Docetaxel (TAXOTERETM) in 31 Medical Oncology Pharma Private Chacko combination with placebo in patients with locally advanced or Limited, Bangalore metastatic (Stage IIIB-IV) non-small cell lung cancer (NSCLC) after failure of 1st Line anti-cancer therapy. D4200C0032. A Phase III, Randomized, Double-blinded, Parallel Group, Multi- centre, study to assess the Efficacy and Safety of ZD6474 AstraZeneca Dr. Raju Titus (ZACTIMATM) in combination with pemetrexed (Alimta®) 32 Medical Oncology Pharma Private Chacko versus Pemetrexed alone in patients with locally advanced or Limited, Bangalore metastatic (stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) after failure of 1st line anti-cancer. 33 Dr. Subhashini John Radiotherapy - II A randomized, double blind, parallel – Group, multicentre, phase AstraZeneca III study comparing the efficacy and tolerability of Fulvestrant Pharma Private (FASLODEXTM) 500mg with Fulvestrant (FASLODEXTM) 250mg Limited, Bangalore in Postmenopausal in Estrogen Receptor Positive advanced breast cancer
Load more

Recommended publications
  • Changing Trend in Diabetes Mellitus
    Acta Scientific Nutritional Health Volume 1 Issue 3 July 2017 Research Article Changing Trend in Diabetes Mellitus Avinash Shankar1*, Abhishek Shankar2, Shubham3, Amresh Shankar4 and Anuradha Shankar5 1Post Graduate in Endocrinology and Metabolism (AIIMS), RA Hospital and Research Centre, Warisaliganj (Nawada) Bihar, India 2All India Institute of Medical Sciences, New Delhi, India 3Max Hospital, Delhi, India 4Medical Officer, State Medical Services, Government of Bihar, Patna, India 5Medical Officer, RBSK, Government of Jharkhand, Ranchi, India *Corresponding Author: Avinash Shankar, Post Graduate in Endocrinology and Metabolism (AIIMS), RA Hospital and Research Centre, Warisaliganj (Nawada) Bihar, India. Received: July 09, 2017; Published: July 28, 2017 Abstract Diabetes mellitus, progressively increasing worldwide but India is considered Diabetes capital of the world with a projected incidence of 109 million by 2035, as this disease of luxury is affecting even down trodden daily wage earner and hard workers both sexes equally due to emergence of toxic non-nutrients in the diet, drinks and oil solely caused by rampant use of fertilizer, chemicals, pesticides, hormones, preservatives and processing. In addition, patients show increased tolerability to high blood sugar level and create suspicion regarding etiopathogenetic of - hyperglycaemia while altered hepatic profile and better glycemic control on adjunction of hepatologic with antidiabetic drug with re 20,000 population of 20 Dalit hamlets and 10 villages of Nawada district aged >
    [Show full text]
  • Determinants of Childhood Immunisation Coverage in Urban Poor Settlements of Delhi, India: a Cross-Sectional Study
    Open Access Research BMJ Open: first published as 10.1136/bmjopen-2016-013015 on 26 August 2016. Downloaded from Determinants of childhood immunisation coverage in urban poor settlements of Delhi, India: a cross-sectional study Niveditha Devasenapathy,1 Suparna Ghosh Jerath,1 Saket Sharma,1 Elizabeth Allen,2 Anuraj H Shankar,3 Sanjay Zodpey1 To cite: Devasenapathy N, ABSTRACT Strengths and limitations of this study Ghosh Jerath S, Sharma S, Objectives: Aggregate data on childhood et al. Determinants of immunisation from urban settings may not reflect the ▪ childhood immunisation We report current estimates of childhood com- coverage among the urban poor. This study provides coverage in urban plete immunisation including hepatitis B vaccine poor settlements of Delhi, information on complete childhood immunisation coverage from representative urban poor com- India: a cross-sectional study. coverage among the urban poor, and explores its munities in the Southeast of Delhi. BMJ Open 2016;6:e013015. household and neighbourhood-level determinants. ▪ The sample size was large and therefore our doi:10.1136/bmjopen-2016- Setting: Urban poor community in the Southeast effect estimates for coverage and determinants 013015 district of Delhi, India. were precise. Participants: We randomly sampled 1849 children ▪ We quantify unknown neighbourhood effects on ▸ Prepublication history and aged 1–3.5 years from 13 451 households in 39 this outcome using median ORs which are more additional material is clusters (cluster defined as area covered by a intuitively understood. available. To view please visit community health worker) in 2 large urban poor ▪ Based on the data, representative of only one the journal (http://dx.doi.org/ settlements.
    [Show full text]
  • Review PANDEMIC TRENDS in PREVALENCE of DIABETES MELLITUS and ASSOCIATED CORONARY HEART DISEASE in INDIA – THEIR CAUSES and PREVENTION
    Review PANDEMIC TRENDS IN PREVALENCE OF DIABETES MELLITUS AND ASSOCIATED CORONARY HEART DISEASE IN INDIA – THEIR CAUSES AND PREVENTION. O P Gupta*, Sanjeev Phatak ** ABSTRACT KEY WORDS: Pandemic, Epidemic; Risk factors The increasing trend of diabetes mellitus (DM) in for diabetes and coronary heat disease. India has become a major health problem. This is also true for the rising magnitude of associated INTRODUCTION coronary heart disease (CHD). In the last 25 years both have acquired pandemic forms, particularly in It is well known that the prevalence of type 2 the urban areas. The comparative studies conducted diabetes mellitus (DM) is rising globally but its in various regions of India till date have been impact is most marked in developing countries like reviewed and they support this trend. The studies on India. Some of the important risk factors associated the migrant population of Indians to various with diabetes are mostly similar in all countries but countries show significant increase in the prevalence their expression and intensities vary widely between of diabetes as compared to the native or other races, regions and countries. Asian Indians have a migrant populations in the same country. The racial predisposition and other unique risk factors to findings and importance of impaired glucose develop DM to a greater extent. In India there is tolerance has been emphasized. The possible causes increasing urbanization and industrialization which of the above increases have been described and has led to physical inactivity, sedentary lifestyle, India-specific factors have been mentioned. psychosocial stress and obesity leading to Particular emphasis has been laid on new and progressive increase in prevalence of DM.
    [Show full text]
  • Analysis of the Universal Immunization Programme and Introduction
    Vaccine 32S (2014) A151–A161 Contents lists available at ScienceDirect Vaccine j ournal homepage: www.elsevier.com/locate/vaccine Analysis of the Universal Immunization Programme and introduction of a rotavirus vaccine in India with IndiaSim a a,b a c Itamar Megiddo , Abigail R. Colson , Arindam Nandi , Susmita Chatterjee , d e a,b,c,∗ Shankar Prinja , Ajay Khera , Ramanan Laxminarayan a Center for Disease Dynamics, Economics & Policy, Washington, DC, USA b Princeton Environmental Institute, Princeton University, Princeton, NJ, USA c Public Health Foundation of India, New Delhi, India d School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India e Ministry of Health and Family Welfare, Government of India, New Delhi, India a b s t r a c t Background and objectives: India has the highest under-five death toll globally, approximately 20% of which is attributed to vaccine-preventable diseases. India’s Universal Immunization Programme (UIP) is working both to increase immunization coverage and to introduce new vaccines. Here, we analyze the disease and financial burden alleviated across India’s population (by wealth quintile, rural or urban area, and state) through increasing vaccination rates and introducing a rotavirus vaccine. Methods: We use IndiaSim, a simulated agent-based model (ABM) of the Indian population (including socio-economic characteristics and immunization status) and the health system to model three interventions. In the first intervention, a rotavirus vaccine is introduced at the current DPT3 immunization coverage level in India. In the second intervention, coverage of three doses of rotavirus and DPT and one dose of the measles vaccine are increased to 90% randomly across the population.
    [Show full text]
  • Chronic Pancreatitis and Pancreatic Diabetes in India
    Chronic Pancreatitis and Pancreatic Diabetes in India DR.RUPNATHJI( DR.RUPAK NATH ) Contents Page No. 1. The changing paradigm of chronic pancreatitis 1-20 David C. Whitcomb 2. Tropical pancreatitis – what is happening to it? 21-51 Balakrishnan V, Nandakumar R, Lakshmi R 3. Tropical pancreatitis in North India 52-59 Gourdas Choudhuri, Eesh Bhatia, Sadiq S Sikora, George Alexander 4. Chronic pancreatitis – the AIIMS, New Delhi experience 60-75 Pramod K. Garg 5. Profile of chronic pancreatitis at the PGIMER, Chandigarh 76-84 Deepak Bhasin, Gursewak Singh, Nagi B, Shoket M Chowdry 6. Chronic pancreatitis – epidemiological and clinical 85-92 spectrum in Jaipur Ramesh Roop Rai, Manish Tandon, Mukul Rastogi, Nijhawan S 7. Chronic pancreatitis in Orissa 93-100 Shivram Prasad Singh 8. Profile of chronic pancreatitis in North Kerala – 101-111 a retrospectiveDR.RUPNATHJI( descriptive study DR.RUPAK NATH ) Varghese Thomas, Harish K 9. Tropical pancreatitis – Data from Manipal 112-115 Ganesh Pai C 10.Etiology and clinical profile of pancreatitis – 116-122 the CMC Vellore experience Ashok Chacko, Shajan Peter 11. Tropical pancreatitis – changing trends 123-132 Vinayakumar KR, Bijulal 12. Exocrine pancreatic function in fibrocalculous 133-141 pancreatic diabetes Mathew Philip, Balakrishnan V 13. Chronic calcific pancreatitis of the tropics with carcinoma 142-149 Meenu Hariharan, Subhalal N, Anandakumar M, Chellam VG, Satheesh Iype 14. Fibrocalculous pancreatic diabetes 150-169 Mohan V 15. Tropical calcific pancreatitis and fibrocalculous pancreatic 170-174 diabetes in Bangladesh Hassan Z, Ali L, Azad Khan AK 16. Fibrocalculous pancreatic diabetes currently seen in 175-187 Lucknow, Uttar Pradesh Eesh Bhatia 17.
    [Show full text]
  • The Economics of Type 2 Diabetes in Middle-Income Countries
    The Economics of Type 2 Diabetes in Middle-Income Countries Till Seuring Doctor of Philosophy (PhD) University of East Anglia, UK Norwich Medical School March 2017 This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with the author and that use of any information derived there from must be in accordance with current UK Copyright Law. In addition, any quotation or extract must include full attribution. Abstract This thesis researches the economics of type 2 diabetes in middle-income coun- tries (MICs). Given the high prevalence of type 2 diabetes in MICs, in-depth country specific analysis is key for understanding the economic consequences of type 2 diabetes. The thesis consists of four studies with the unifying theme of improving the understanding of the causal impact of diabetes on economic out- comes. Study (1) provides an updated overview, critically assesses and identifies gaps in the current literature on the economic costs of type 2 diabetes using a systematic review approach; study (2) investigates the effects of self-reported diabetes on employment probabilities in Mexico, using cross-sectional data and making use of a commonly used instrumental variable approach; study (3) re- visits and extends these results via the use of a fixed effects panel data analy- sis, also considering a broader range of outcomes, including wages and working hours. Further, it makes use of cross-sectional biomarker data that allow for the investigation of undiagnosed diabetes. Study (4) researches the effect of a dia- betes diagnosis on employment as well as behavioural risk factors in China, using longitudinal data and applying an alternative identification strategy, marginal structural models estimation, while comparing these results with fixed effects es- timation results.
    [Show full text]
  • Why Is the Vaccination Rate Low in India?
    medRxiv preprint doi: https://doi.org/10.1101/2021.01.21.21250216; this version posted February 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Why is the Vaccination Rate Low in India? First Version: 21st January 2021 This Version: 15th February 2021 Pramod Kumar Sur Asian Growth Research Institute (AGI) and Osaka University [email protected] Abstract India has had an established universal immunization program since 1985 and immunization services are available for free in healthcare facilities. Despite this, India has one of the lowest vaccination rates globally and contributes to the largest pool of under-vaccinated children in the world. Why is the vaccination rate low in India? This paper explores the importance of historical events in shaping India’s current vaccination practices. We examine India’s aggressive family planning program implemented during the period of emergency rule in the 1970s, under which millions of individuals were forcibly sterilized. We find that greater exposure to the forced sterilization policy has had negative effects on the current vaccination rate. We also find that institutional delivery and antenatal care are currently low in states where policy exposure is high. Together, the evidence suggests that the forced sterilization policy has had a persistent effect on current health-seeking behavior in India. Keywords: Vaccination, family planning, sterilization, institutional delivery, antenatal care, persistence JEL Classification: N35, I15, I18, O53, Z1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • A Brief History of Vaccines & Vaccination in India
    [Downloaded free from http://www.ijmr.org.in on Wednesday, August 26, 2020, IP: 14.139.60.52] Review Article Indian J Med Res 139, April 2014, pp 491-511 A brief history of vaccines & vaccination in India Chandrakant Lahariya Formerly Department of Community Medicine, G.R. Medical College, Gwalior, India Received December 31, 2012 The challenges faced in delivering lifesaving vaccines to the targeted beneficiaries need to be addressed from the existing knowledge and learning from the past. This review documents the history of vaccines and vaccination in India with an objective to derive lessons for policy direction to expand the benefits of vaccination in the country. A brief historical perspective on smallpox disease and preventive efforts since antiquity is followed by an overview of 19th century efforts to replace variolation by vaccination, setting up of a few vaccine institutes, cholera vaccine trial and the discovery of plague vaccine. The early twentieth century witnessed the challenges in expansion of smallpox vaccination, typhoid vaccine trial in Indian army personnel, and setting up of vaccine institutes in almost each of the then Indian States. In the post-independence period, the BCG vaccine laboratory and other national institutes were established; a number of private vaccine manufacturers came up, besides the continuation of smallpox eradication effort till the country became smallpox free in 1977. The Expanded Programme of Immunization (EPI) (1978) and then Universal Immunization Programme (UIP) (1985) were launched in India. The intervening events since UIP till India being declared non-endemic for poliomyelitis in 2012 have been described. Though the preventive efforts from diseases were practiced in India, the reluctance, opposition and a slow acceptance of vaccination have been the characteristic of vaccination history in the country.
    [Show full text]
  • Accessing Health Services in India: Experiences of Seasonal Migrants Returning to Nepal
    Accessing health services in India: Experiences of seasonal migrants returning to Nepal. Pratik Adhikary ( [email protected] ) Tribhuvan University https://orcid.org/0000-0003-1678-1692 Nirmal Aryal Bournemouth University Raja Ram Dhungana Victoria University Radheyshyam Krishna KC International Organization for Migration Pramod Raj Regmi Bournemouth University Kolitha Prabhash Wickramage International Organization for Migration Patrick Duigan International Organization for Migration Montira Inkochasan International Organization for Migration Guna Nidhi Sharma National Health Research Institutes Institute of Population Health Sciences Bikash Devkota National Health Research Institutes Institute of Population Health Sciences Edwin van Teijlingen Bournemouth University Padam Simkhada University of Hudderseld Research article Keywords: Migrants, Returnees, Healthcare access, Qualitative research, Nepal, South Asia Posted Date: September 2nd, 2020 DOI: https://doi.org/10.21203/rs.3.rs-31011/v2 Page 1/13 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Version of Record: A version of this preprint was published on October 29th, 2020. See the published version at https://doi.org/10.1186/s12913-020-05846-7. Page 2/13 Abstract Background: Migration to India is a common livelihood strategy for poor people in remote Western Nepal. To date, little research has explored the degree and nature of healthcare access among Nepali migrant workers in India. This study explores the experiences of returnee Nepali migrants with regard to accessing healthcare and the perspectives of stakeholders in the government, support organizations, and health providers working with migrant workers in India. Methods: Six focus group discussions (FGDs) and 12 in-depth interviews with returnee migrants were conducted by trained moderators in six districts in Western Nepal in late 2017.
    [Show full text]
  • Christian Medical College Vellore This Prospectus Is Common to All Courses Around the Year and Needs to Be Read with the Appropriate Admission Bulletin for the Course
    Admissions 2018-2019 Christian Medical College Vellore This prospectus is common to all courses around the year and needs to be read with the appropriate admission bulletin for the course ALL COURSES AND ADMISSIONS TO OUR COLLEGE ARE SUBJECT TO APPLICABLE REGULATIONS BY UNIVERSITY/GOVERNMENT/MEDICAL COUNCIL OF INDIA/NATIONAL BOARD OF EXAMS NO FEE OR DONATION OR ANY OTHER PAYMENTS ARE ACCEPTED IN LIEU OF ADMISSIONS, OTHER THAN WHAT HAS BEEN PRESCRIBED IN THE PROSPECTUS THE GENERAL PUBLIC ARE THEREFORE CAUTIONED NOT TO BE LURED BY ANY PERSON/ PERSONS OFFERING ADMISSION TO ANY OF THE COURSES CONDUCTED BY US SHOULD ANY PROSPECTIVE CANDIDATE BE APPROACHED BY ANY PERSON/PERSONS, THIS MAY IMMEDIATELY BE REPORTED TO THE LAW ENFORCEMENT AGENCIES FOR SUITABLE ACTION AND ALSO BROUGHT TO THE NOTICE OF OUR COLLEGE AT THE ADDRESS GIVEN BELOW OUR COLLEGE WILL NOT BE RESPONSIBLE FOR ANY CANDIDATES OR PARENTS DEALING WITH SUCH PERSONS CORRESPONDENCE All correspondence should refer to the Application number or to the Hall Ticket number and be addressed to: The Registrar Christian Medical College, Vellore-632002 Tamil Nadu, India Phone: (0416)2284255 Fax: (0416) 2262788 Email: [email protected] Website: http://admissions.cmcvellore.ac.in PLEASE NOTE: WE DO NOT ADMIT STUDENTS THROUGH AGENTS OR AGENCIES Important Information: “The admission process contained in this Bulletin shall be subject to any order that maybe passed by the Hon’ble Supreme Court or the High Court in the proceedings relating to the challenge to the NEET, common counselling or
    [Show full text]
  • IJPP Hemotology 9-2-08
    2009; 11(1) : 1 INDIAN JOURNAL OF IJPP PRACTICAL PEDIATRICS • • IJPP is a quarterly subscription journal of the Indian Academy of Pediatrics committed to presenting practical pediatric issues and management updates in a simple and clear manner • • Indexed in Excerpta Medica, CABI Publishing. Vol.11 No.1 JAN.-MAR.2009 Dr. K.Nedunchelian Dr. S. Thangavelu Editor-in-Chief Executive Editor CONTENTS FROM THE EDITOR'S DESK 3 TOPIC OF INTEREST - TOXICOLOGY Organophosphate, carbamate and rodenticide poisoning 6 - Rajendiran C, Ravi G, Thirumalaikolundu Subramanian P Hydrocarbon and related compounds poisoning 15 - Utpal Kant Singh, Prasad R, Gaurav A Common drug poisoning 22 - Suresh Gupta Corrosive poisoning 37 - Jayanthi Ramesh House hold material poisoning 41 - Shuba S, Betty Chacko Cardiotoxins 53 - Rashmi Kapoor Narcotic poisoning 64 - Kala Ebinazer Journal Office and address for communications: Dr. K.Nedunchelian, Editor-in-Chief, Indian Journal of Practical Pediatrics, 1A, Block II, Krsna Apartments, 50, Halls Road, Egmore, Chennai - 600 008. Tamil Nadu, India. Tel.No. : 044-28190032 E.mail : [email protected] 1 Indian Journal of Practical Pediatrics 2009; 11(1) : 2 GENERAL ARTICLES Intrauterine growth retardation : Journey from conception to late adulthood 68 - Neelam Kler, Naveen Gupta Child adoption 82 - Ganesh R, Suresh N, Eswara Raja T, Lalitha Janakiraman, Vasanthi T DERMATOLOGY Ichthyosis - An approach 86 - Anandan V PICTURE QUIZ 91 RADIOLOGIST TALKS TO YOU Disorders of ventral induction and similar conditions - I 92 - Vijayalakshmi G, Elavarasu E, Vijayalakshmi M, Venkatesan MD CASE STUDY Unusual complication of nasogastric tube insertion in a child 95 - Poovazhagi V, Shanthi S, Vijayaraghavan A, Kulandai Kasturi R Congenital miliary tuberculosis 97 - Vijayakumari, Suresh DV CLIPPINGS 14,21,52,63,81,94 NEWS AND NOTES 85,90 FOR YOUR KIND ATTENTION * The views expressed by the authors do not necessarily reflect those of the sponsor or publisher.
    [Show full text]
  • Association Between Socioeconomic Status and Self-Reported Diabetes in India: a Cross-Sectional Multilevel Analysis
    Association between socioeconomic status and self-reported diabetes in India: a cross-sectional multilevel analysis The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Corsi, Daniel J, and S V Subramanian. 2012. Association between socioeconomic status and self-reported diabetes in India: a cross- sectional multilevel analysis. BMJ Open 2(4): e000895. Published Version doi:10.1136/bmjopen-2012-000895 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10576035 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Open Access Research Association between socioeconomic status and self-reported diabetes in India: a cross-sectional multilevel analysis Daniel J Corsi,1 S V Subramanian2 To cite: Corsi DJ, ABSTRACT ARTICLE SUMMARY Subramanian SV. Association Objectives: To quantify the association between between socioeconomic socioeconomic status (SES) and type 2 diabetes in status and self-reported Article focus India. - diabetes in India: The relationship between socioeconomic factors a cross-sectional multilevel Design: Nationally representative cross-sectional and type 2 diabetes has not been previously analysis. BMJ Open 2012;2: household survey. studied for the whole of India and across states. e000895. doi:10.1136/ Setting: Urban and rural areas across 29 states in - Our objective was to investigate associations bmjopen-2012-000895 India. between measures of SES (defined as social Participants: 168 135 survey respondents aged caste, education, household wealth) and self- < Prepublication history and 18e49 years (women) and 18e54 years (men).
    [Show full text]